| 4.85 0.05 (1.04%) | 04-19 10:01 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 6.23 | 1-year : | 7.28 |
| Resists | First : | 5.34 | Second : | 6.23 |
| Pivot price | 4.94 |
|||
| Supports | First : | 4.52 | Second : | 4.01 |
| MAs | MA(5) : | 4.89 |
MA(20) : | 4.93 |
| MA(100) : | 4.71  |
MA(250) : | 4.06 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 28.8 |
D(3) : | 38 |
| RSI | RSI(14): 47.4 |
|||
| 52-week | High : | 7.36 | Low : | 2.13 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ SOPH ] has closed above bottom band by 11.9%. Bollinger Bands are 60% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 7 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 5.01 - 5.04 | 5.04 - 5.06 |
| Low: | 4.63 - 4.67 | 4.67 - 4.69 |
| Close: | 4.8 - 4.85 | 4.85 - 4.89 |
SOPHiA GENETICS SA operates as a healthcare technology company. The company offers SOPHiA DDM platform, a cloud-based software-as-a-service platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, products, and services are used by hospital, laboratory, and biopharma worldwide. SOPHiA GENETICS SA was incorporated in 2011 and is headquartered in Saint-Sulpice, Switzerland.
Sat, 13 Apr 2024
Short Interest in SOPHiA GENETICS SA (NASDAQ:SOPH) Grows By 22.3% - MarketBeat
Thu, 04 Apr 2024
SOPHiA GENETICS and Strand Life Sciences Announce New Strategic Partnership - Marketscreener.com
Sat, 09 Mar 2024
SOPHiA GENETICS SA (NASDAQ:SOPH) Just Released Its Yearly Results And Analysts Are Updating Their Estimates - Yahoo Finance
Sat, 09 Mar 2024
SOPHiA GENETICS SA (NASDAQ:SOPH) Full-Year Results Just Came Out: Here's What Analysts Are Forecasting For This Year - Simply Wall St
Wed, 06 Mar 2024
SOPHiA GENETICS SA (NASDAQ:SOPH) Q4 2023 Earnings Call Transcript - Yahoo Finance
Tue, 05 Mar 2024
Why SOPHiA GENETICS Shares Are Trading Lower By 19%? Here Are Other Stocks Moving In Tuesday’s Mid-Day Se - Benzinga
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Healthcare Information Services
|
|
| Shares Out | 65 (M) |
| Shares Float | 46 (M) |
| Held by Insiders | 5.9 (%) |
| Held by Institutions | 49.9 (%) |
| Shares Short | 53 (K) |
| Shares Short P.Month | 60 (K) |
| EPS | -1.23 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.31 |
| Profit Margin | -126.7 % |
| Operating Margin | -111 % |
| Return on Assets (ttm) | -20.8 % |
| Return on Equity (ttm) | -45 % |
| Qtrly Rev. Growth | 27.3 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0.95 |
| EBITDA (p.s.) | -1.12 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -49 (M) |
| Levered Free Cash Flow | -31 (M) |
| PE Ratio | -3.94 |
| PEG Ratio | 0 |
| Price to Book value | 2.06 |
| Price to Sales | 5.02 |
| Price to Cash Flow | -6.46 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|